(Q38032598)

27 August 2017

title

Abatacept in the treatment of lupus (English)

1 reference

27 August 2017

Alberta Y Hoi

1

1 reference

27 August 2017

Geoffrey O Littlejohn

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

7 August 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1399-1406

1 reference

Autoimmunity through cytokine-induced dendritic cell activation

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Novel therapeutics for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

A fundamental role for interleukin-21 in the generation of T follicular helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Clinical trial design in systemic lupus erythematosus: lessons learned and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.713934

10.1517/14712598.2012.713934

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference